statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

4D Molecular Therapeutics (NASDAQ:FDMT - Free Report) had its price objective reduced by BMO Capital Markets from $70.00 to $63.00 in a research note published on Monday, Benzinga reports. They...

BMO Capital Markets Trims 4D Molecular Therapeutics (NASDAQ:FDMT) Target Price to $63.00

4D Molecular Therapeutics Inc (FDMT) Chief Legal Officer Scott Bizily Sells 8,153 Shares

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) had its target price increased by equities research analysts at Jefferies Financial Group from $30.00 to $58.00 in a report released on...

4D Molecular Therapeutics (NASDAQ:FDMT) PT Raised to $58.00 at Jefferies Financial Group

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) insider Scott Bizily sold 5,833 shares of the stock in a transaction on Wednesday, March 27th. The stock was sold at an average price...

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Insider Sells $204,388.32 in Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) insider Scott Bizily sold 5,833 shares of the stock in a transaction dated Wednesday, March 27th. The shares were sold at an average...

Scott Bizily Sells 5,833 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock

4D Molecular Therapeutics Inc's Chief Legal Officer Sells Company Shares

Leerink Partners analyst Mani Foroohar has maintained their bullish stance on FDMT stock, giving a Buy rating yesterday. Mani Foroohar's rating is...

Optimistic Outlook for 4D Molecular Therapeutics Ahead of Regulatory Update on CF Gene Therapy 4D-710

This is a signal that FDMT's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

4D Molecular Therapeutics (FDMT, $31.83) RSI Indicator left the overbought zone on March 28, 2024

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT  Get Free Report)s stock price hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $35.72 and last...

4D Molecular Therapeutics (NASDAQ:FDMT) Sets New 1-Year High at $35.72

Conducted initial pivotal study interactions with the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA); Company has clear registration path for 4D-710 for treatment of...

4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis

4D Molecular Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of unlocking the full potential of genetic medicines to treat large market diseases in ophthalmology and pulmonology. The firm also offers product candidates focused on large market ophthalmology, pulmonology, and cardiology. The company was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.

Volume	320,319.00
52-Wk High	$36.25
52-Wk Low	$9.44

Period	Estimated	Reported	Surprise	Result
Q1'24	-$0.74	--	--	N/A
Q4'23	-$0.73	-$0.69	4.96%	BEAT
Q3'23	-$0.61	-$0.24	60.86%	BEAT
Q2'23	-$0.78	-$0.77	1.75%	BEAT
Q1'23	-$0.89	-$0.88	1.49%	BEAT

FDMT 4D Molecular Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals